Lotus Pharm (1795) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 美時

Lotus Pharm (1795) reported revenue of NT$2.13 billion for Oct 2026, -22.5% year on year and -22.8% from the previous month. Revenue for Jan–Oct 2026 was NT$26.95 billion (+58.5% year on year).

In Oct 2026, it ranked No. 2 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$1.88 billion24/10Nov 2024 NT$1.06 billionDec 2024 NT$1.46 billionJan 2025 NT$2.17 billionFeb 2025 NT$966.7 million25/02Mar 2025 NT$1.59 billionApr 2025 NT$2.57 billionMay 2025 NT$1.13 billionJun 2025 NT$1.04 billion25/06Jul 2025 NT$2.4 billionAug 2025 NT$1.16 billionSep 2025 NT$1.21 billionOct 2025 NT$2.75 billion25/10Nov 2025 NT$1.06 billionDec 2025 NT$2.44 billionJan 2026 NT$2.05 billionFeb 2026 NT$2.24 billion26/02Mar 2026 NT$4.35 billionApr 2026 NT$3.09 billionMay 2026 NT$2.32 billionJun 2026 NT$3.4 billion26/06Jul 2026 NT$2.49 billionAug 2026 NT$2.11 billionSep 2026 NT$2.77 billionOct 2026 NT$2.13 billion26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$2.13 billion-22.5%-22.8%
Sep 2026NT$2.77 billion+128.0%+31.3%
Aug 2026NT$2.11 billion+81.7%-15.4%
Jul 2026NT$2.49 billion+3.9%-26.7%
Jun 2026NT$3.4 billion+225.5%+46.2%
May 2026NT$2.32 billion+105.8%-24.7%
Apr 2026NT$3.09 billion+19.9%-29.1%
Mar 2026NT$4.35 billion+173.6%+94.5%
Feb 2026NT$2.24 billion+131.5%+9.1%
Jan 2026NT$2.05 billion-5.5%-16.0%
Dec 2025NT$2.44 billion+66.9%+130.7%
Nov 2025NT$1.06 billion-0.2%-61.5%
Oct 2025NT$2.75 billion+46.0%+126.9%
Sep 2025NT$1.21 billion+2.3%+4.6%
Aug 2025NT$1.16 billion-12.5%-51.6%
Jul 2025NT$2.4 billion-11.9%+129.6%
Jun 2025NT$1.04 billion-6.3%-7.5%
May 2025NT$1.13 billion-27.3%-56.1%
Apr 2025NT$2.57 billion+23.9%+61.7%
Mar 2025NT$1.59 billion+38.3%+64.7%
Feb 2025NT$966.7 million-8.1%-55.5%
Jan 2025NT$2.17 billion+8.8%+48.4%
Dec 2024NT$1.46 billion+6.6%+38.0%
Nov 2024NT$1.06 billion-6.6%-43.7%
Oct 2024NT$1.88 billion+106.8%+58.8%

Jan–Oct 2026 cumulative: NT$26.95 billion (+58.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Lotus Pharm vs PEC / Lotus Pharm vs Bora / Lotus Pharm vs Great Tree Pharmacy

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%
GKB1707NT$748.3 million-30.8%

Company remark (original Chinese)

本年累計營收較去年同期增加主係受惠於併購NAGH後的營收挹注及出口業務成長所致。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16